in the context of the present invention , there has been found in particular the synergistic anti - inflammatory action of monoterpenes and topical respiratory therapeutics ( for example inhalative glucocorticoids ). particularly surprisingly , as the basis of the present invention , it has been found that therapeutically relevant concentrations of 1 , 8 - cineol significantly increase the anti - inflammatory action of topical respiratory therapeutics , in particular topical glucocorticoids , by synergistic inhibition of the cytokine production . the applicant was able to demonstrate a synergistic anti - inflammatory action of monoterpenes and topical respiratory therapeutics , in particular topical glucocorticoids . thus , for example , even low therapeutic concentrations of 1 , 8 - cineol ( for example 10 − 6 mol / l ) inhibit the production of il - 1beta significantly compared to subtherapeutic concentrations of beclometasone , for which , when used on its own , no significant inhibition could be demonstrated . in contrast , by combining 1 , 8 - cineol and inhalative glucocorticoid ( beclometasone ), a significant inhibition could be demonstrated even for subtherapeutic and therapeutic concentrations of beclometasone with a resulting more intensive action of ics . more detailed clinical studies show that it is possible to reduce the dose of the inhalative ics by up to 30 % to 50 % and more during a systemic long - term therapy with 1 , 8 - cineol ( for example soledum ® capsules ). the essential clinical meaning is that the anti - inflammatory action of minimal concentrations , which decrease in the periphery of the lung , of common ics ( metered aerosols and powder preparations ) becomes more intensive . the use of the combination according to the invention of systemic monoterpene and topical respiratory therapeutic , in particular topical glucocorticoid , ( for example oral 1 , 8 - cineol and ics or beclometasone ) is advantageous in particular in the therapy of a peripheral respiratory inflammation in bronchial asthma and copd as a novel therapeutic concept and for modulating the steroid - refractory progression of the pulmonary disorder , to prevent the development of irreversible respiratory insufficiency . however , of particular clinical value is the therapeutic use of monoterpenes , in particular 1 , 8 - cineol , for the prophylaxis and therapy of early forms of copd ( gold 0 or gold i ), for which there is currently no anti - inflammatory therapy recommended by all lung associations world - wide . furthermore , by a combined therapy of systemic monoterpene and topical respiratory therapeutic , in particular topical glucocorticoid ( for example oral 1 , 8 - cineol and ics or beclometasone ), the steroid - refractory respiratory inflammation caused by cigarette smoke and also other harmful proinflammatory or oxidative environmental substances such as , in particular , ozone ( o 3 ), and the development of copd is inhibited prophylactically and / or therapeutically . a further essential aspect of the present invention is in particular also the prophylactic and alleviating effect of monoterpenes , in particular 1 , 8 - cineol , in combination with topical respiratory therapeutics , in particular topical glucocorticoids , or else of monoterpenes on their own , in particular 1 , 8 - cineol , on inflammations in smokers for the prevention and amelioration of the damage to the respiratory tract caused by cigarette smoke . this damage occurs in particular even many years after smoking cessation or after the action of other noxious substances and is characterized clinically by a progressive obstruction and the development of emphysema with respiratory insufficiency during ongoing antiobstructive therapy . especially using the monoterpene 1 , 8 - cineol as additional therapy with modern combined therapy forms ( for example ics plus laba or ics in combination with vagolytics or else ics or saba on their own ), in long - term therapy , surprisingly , in former smokers who had ceased smoking more than ten years previously , an inhibition of the production of tnf - α and an increased production of il - 8 in ex - vivo stimulated peripheral human monocytes was found compared to normal monocytes of nonsmokers . from these patients , monocytes were obtained during ongoing therapy with ics and incubated in vitro with a topical glucocorticoid in a dose - dependent manner . in particular in comparison with a group of normal subjects not undergoing therapy with 1 , 8 - cineol , the results show , with earlier onset , a more pronounced inhibitory action on the production of il - 8 and tnf - α in monocytes of patients with copd . these results lead to the new finding that the inhibition of steroid - sensitive mechanisms alone is not able to have a sufficient effect on the course of the disease , so that a systemic additional therapy with monoterpenes decisively improves persistent respiratory inflammation in copd , helps to reduce exacerbations in persisting inflammations and in particular in the periphery intensifies the action of smaller concentrations , relevant for the respiratory tract , of topical glucocorticoids or other inhalative respiratory therapeutics . currently , the inhibition of exacerbations is one of the most important therapeutic aims in smokers and former smokers suffering from copd which can be ameliorated by the non - steroidal effects of the monoterpene 1 , 8 - cineol . in addition , 1 , 8 - cineol enhances anti - inflammatory and antiobstructive effects of topical respiratory therapeutics , in particular topical glucocorticoids , so that even hitherto unknown pharmaceutical combinations of , for example , ics and 1 , 8 - cineol or another monoterpene , laba and 1 , 8 - cineol , saba and 1 , 8 - cineol and also of ics , saba and 1 , 8 - cineol or of ics , laba and 1 , 8 - cineol are suitable as a therapeutical alternative to the therapy of asthma and copd of all degrees of severity and for the additional treatment of the active systemic component in copd by the systemic availability of monoterpenes , in particular in capsules which dissolve in the small intestine or as powders . in the context of the present invention , in the search for the underlying property of monoterpenes , in particular 1 , 8 - cineol , which intensifies anti - inflammatory actions of topical steroids , the applicant has additionally found an antioxidative action of 1 , 8 - cineol due to inhibition of the production of superoxides ( o 2 − radicals ), the activity of superoxide dismutases ( sod ) and of hydrogen peroxide ( h 2 o 2 ) which as end product of the oxidation stimulates the production of inflammation mediators , in particular of cytokines and arachidonic acid metabolites . here , for the first time , an inhibition of the spontaneous production of o 2 − radicals was demonstrated at therapeutic concentrations of 1 , 8 - cineol which , at relatively low concentrations relevant for respiratory air , stimulates o 2 − radicals and in the therapeutic range inhibits the production of o 2 − radicals and h 2 o 2 . the cause of these antioxidative actions of 1 , 8 - cineol was surprisingly found to be 1 , 8 - cineol as active inducer of no production which , via this mechanism , removes o 2 − from the organism as substrate for the formation of no production . it has thus been found that monoterpenes such as 1 , 8 - cineol actively induce no production by mediating antioxidative effects . here , for the first time , it was possible to demonstrate modulating effects of 1 , 8 - cineol for controlling oxidative , cell - damaging and proinflammatory effects by inhibition of o 2 − radicals and a contrary stimulation of anti - inflammatory and vasodilatory no in the therapeutic range of 1 , 8 - cineol . these results are of integral importance for the prophylaxis and therapy , in particular of pulmonary disorders associated with cigarette smoking , including pulmonary emphysema and the regulation of the tone of pulmonary vessels , and also of damage to greater and lesser circulation . thus , an increased production of o 2 − radicals is mediated by cigarette smoke , infections , nanoparticles , ozone , allergens and other environmental effects which can be inhibited permanently by a long - term therapy with 1 , 8 - cineol and moreover can be utilized advantageously as a substrate for the production of no . no is known to be an anti - inflammatory mediator , vasodilator , inhibitor of inflammatory mediators , histamine , granulocyte adhesion and platelet aggregation and also as an activator of ciliary function and mucosal clearance and protects comprehensively against respiratory infections and exacerbations of asthma and copd in all disease stages . in this respect , 1 , 8 - cineol is suitable as a continuous therapeutic which , in chronic bronchitis , copd , emphysema and rhinosinusitis , by modulation , normalizes and adequately adapts to the respective requirements a suppressed no production by favourable degradation of o 2 − radicals with induction of no . this leads in particular to novel indications for the use of monoterpenes , in particular 1 , 8 - cineol , preferably in a relatively high , systemically effective daily dose of , for example , from 600 to 1200 mg , to regulate organ perfusion and to protect the upper and lower respiratory tracts including the lung against noxious substances acting as pathogens , in particular cigarette smoke , respiratory infections and allergic and non - allergic respiratory inflammation in cases of hyperactivity , asthma and rhinitis . to summarize : the findings discovered in the context of the present invention about monoterpenes lead to a completely new understanding of the group , previously not recognized by the person skilled in the art , of secretolytics and mucolytics including natural ethereal oils or mixed terpenes , ambroxol and n - acetylcysteine , whose use hitherto served primarily to loosen mucus , but not causally to release no or to modulate other mechanisms and thus not primarily for the prophylaxis and therapy of multifactorial respiratory inflammation . this means that the conventional temporally limited therapy with in most cases ineffective substances targets only actual mucus hypersecretion and that therefore a long - term therapy to prevent the development and progression of respiratory inflammation in copd and asthma by early use of effective substances with combined antioxidative and anti - inflammatory activity profile and a non - steroidal anti - inflammatory mechanism of action for enhancing the activity of topical respiratory therapeutics , in particular glucocorticoids , and also good compatibility without steroid side - effects in contrast to the general guidelines of national and international lung associations should be proposed as a matter of urgency . here , effective substances , such as monoterpenes , in particular 1 , 8 - cineol , may play a more central role in the future owing to their better availability in the respiratory tract as a consequence of their high lipophilicity and the exhalation of the active compound after alveolar uptake from the bloodstream into the pulmonary periphery . therefore , for monoterpenes , in particular 1 , 8 - cineol , a new classification as belonging to a novel group of substances as “ non - steroidal airway inflammation modifier ( nsaim )” should be proposed . further embodiments , adaptations and variations and also advantages of the present invention are readily discernible and feasible for the person skilled in the art on reading the description , without the person leaving the scope of the present invention . the following working examples serve only to illustrate the present invention , without the invention being limited thereto . in in vitro studies , it was found that monoterpenes ( here specifically : 1 , 8 - cineol ) are capable of enhancing the activity of inhalative respiratory therapeutics , in particular glucocorticoids ( here specifically : beclometasone ), in a significant , in particular synergistic , manner . surprisingly , it has been found that therapeutically relevant concentrations of 1 , 8 - cineol significantly enhance the anti - inflammatory action of topical glucocorticoids by synergistic inhibition of cytokine production ( see table 1 ). table 1 shows the synergistic activity of 1 , 8 - cineol ( 10 − 6 mol / l ) and beclometasone on the lps - stimulated production of il - 1beta in human monocytes in vitro . monocyte il - 1beta production ( n = 14 - 15 , 4 experiments ) in monocytes is inhibited significantly by cineol ( 10 − 6 mol / l ) compared to the control . cineol and beclometasone synergistically inhibit il - 1beta production more than beclometasone on its own . compared to cineol ( 10 − 6 mol / l ) on its own , the il - 1beta production is also inhibited synergistically and to a significantly more pronounced degree by addition of beclometasone ( p & lt ; 0 . 05 ). the monocyte il - 1beta production ( n = 14 - 15 , 4 experiments ) in monocytes is inhibited significantly by 1 , 8 - cineol ( 10 − 6 mol / l ) compared to the control . 1 , 8 - cineol and beclometasone synergistically inhibit the il - 1beta own . compared to cineol ( 10 mol / l ), the il - 1beta production is also inhibited synergistically and to a significantly more pronounced degree by addition of beclometasone ( p & lt ; 0 . 05 ). the results from human monocyte cultures show for the first time that the lps - stimulated production of il - 1beta is inhibited to a significantly more pronounced degree ( p & lt ; 0 . 01 ) by beclometasone and 1 , 8 - cineol 10 − 6 mol / l ( 73 . 4 ± 19 %) tahn by beclometasone on its own ( 49 . 9 ± 20 %) or 1 , 8 - cineol on its own ( 32 . 4 ± 17 %) ( see fig1 and 2 ). this is the first demonstration of a synergistic anti - inflammatory action of systemic monoterpenes and topical glucocorticoids . in this context , fig1 shows the stimulation of the action of the inhalative corticosteroid beclometasone by the monoterpene 1 , 8 - cineol ( 10 − 6 mol / l ) in lps - stimulated human monocytes in vitro ; the addition even of small amounts of 1 , 8 - cineol effects a significant increase of the activity of beclometasone , associated with an increased inhibition of il - 1beta . fig1 shows the synergistic action of 1 , 8 - cineol and beclometasone : for 20 hours , monocytes ( n = 14 - 15 , 4 experiments ) of healthy subjects ( 10 5 / ml ) were incubated with 1 , 8 - cineol ( 10 − 6 mol / 1 = 0 . 015 μg / ml ) and beclometasone ( 10 − 12 - 10 − 9 mol / l ) in the presence of lps ( 10 mg / ml ). in cell culture supernatants , the production of il - 1beta was determined by elisa ( from cayman , annarbor , mich ., usa ). 1 , 8 - cineol on its own (− 32 %± 17 %, p = 0 . 01 ) and therapeutically relevant concentrations of beclometasone ( 10 − 9 mol / l , p = 0 . 045 ) inhibit the production of il - 1beta . in contrast , the lps - stimulated production is inhibited to a significantly more pronounced degree ( p & lt ; 0 . 031 ) by a combination of 1 , 8 - cineol ( 10 − 6 mol / l ) plus beclometasone ( 10 − 11 - 10 − 9 mol / l ) than by beclometasone on its own . 1 , 8 - cineol intensifies in particular the action of subtherapeutic concentrations of beclometasone which are relevant for the peripheral respiratory tract . fig2 shows the effects of 1 , 8 - cineol on the il - 1beta inhibition by beclometasone in vitro . fig2 likewise illustrates the synergistic action of 1 , 8 - cineol and beclometasone at higher therapeutic concentrations : the lps - stimulated production of il1 - beta ( n = 14 - 15 , 4 experiments ) is inhibited by therapeutically relevant concentrations of 1 , 8 - cineol in a dose - dependent manner and significantly ( p & lt ; 0 . 01 ) compared to the lps control . the activity of therapeutically relevant concentrations of beclometasone is inhibited significantly ( p & lt ; 0 . 01 ) more strongly by 1 , 8 - cineol compared to beclometasone plus 1 , 8 - cineol . to achieve this activity , concentrations of the two substances which are at least 10 times higher have to be present . furthermore , the results allow it to be demonstrated for the first time that even low therapeutic concentrations of 1 , 8 - cineol ( 10 − 6 mol / l ) significantly inhibit the production of il - 1beta compared to subtherapeutic concentrations of beclometasone ( beclometasone : 10 − 12 mol / 1 : 0 %; 10 − 11 mol / 1 : − 19 . 7 %± 20 %; 10 − 10 mol / 1 : − 22 . 9 %± 13 %) for which no significant inhibition was shown . in contrast , by combining 1 , 8 - cineol and beclometasone a significant inhibition could be demonstrated even for subtherapeutic and therapeutic concentrations of beclometasone with a resulting increase in the action of ics . these findings confirm the clinical data given below with respect to a significant reduction of the inhalative ics dose of up to 60 % during long - term therapy with oral 1 , 8 - cineol ( soledum ® capsules ). a further essential novel aspect of the present data is the prophylactic and alleviating effect of 1 , 8 - cineol in combination with topical glucocorticosteroids or else by 1 , 8 - cineol on its own on inflammations in smokers for the prevention and amelioration of the damage to the respiratory tract caused by cigarette smoke . this damage occurs in particular even many years after smoking cessation or after the action of other noxious substances and is characterized clinically by a progressive obstruction and the development of emphysema with respiratory insufficiency during ongoing antiobstructive therapy . with respect to the recommended combined standard therapies of long - acting beta - 2 - sympathomimetics ( laba ), short - acting beta - 2 - sympathomimetics ( saba ) and inhalative steroids ( ics ), novel , hitherto unknown options for additional therapy with 1 , 8 - cineol result , with the aim of enhancing effects of topical therapy and to treat a respiratory disorder now identified as a systemic disorder in a combined manner topically and systemically with additional intensification of the topical anti - inflammatory and bronchodilatatory therapy as systemic disorder by long - term therapy . currently , the inhibition of exacerbations is one of the most important therapeutic targets for smokers and former smokers with copd which can be ameliorated by the non - steroidal effects of the monoterpene 1 , 8 - cineol . in addition , 1 , 8 - cineol improves anti - inflammatory and antiobstructive effects of ics plus laba , so that hitherto unknown pharmaceutical combination products or kits consisting , for example , of ics + 1 , 8 - cineol or another monoterpene , laba + 1 , 8 - cineol , saba + 1 , 8 - cineol or else ics + saba + 1 , 8 - cineol or ics + laba + 1 , 8 - cineol , and also modern combinations with long - acting vagolytics will be suitable in the future as a therapeutic alternative for the therapy of asthma and copd in all degrees of severity and for the additional treatment of the active systemic component in copd owing to the systemic availability of monoterpenes in the form of capsules which dissolve in the small intestine or as powders . in the context of the present invention , for the first time , modulating antioxidative and anti - inflammatory effects of monoterpenes ( 1 , 8 - cineol ) could be demonstrated for controlling oxidative processes and for the induction of nitric oxide production ( no production ). in the search for the underlying property of monoterpenes , in particular 1 , 8 - cineol , for the intensification of anti - inflammatory actions of topical steroids , an antioxidative action of 1 , 8 - cineol owing to inhibition of the production of superoxides ( o 2 − radicals ), the activity of superoxide dismutases ( sod ) and of hydrogen peroxide ( h 2 o 2 ) has been found . here , for the first time , an inhibition of the spontaneous and stimulated production of superoxides ( o 2 − radicals ) was demonstrated at therapeutic concentrations of 1 , 8 - cineol , so that the provision of the substrate for the dismutation of o 2 − radicals via a superoxide dismutase activity partially inhibited by 1 , 8 - cineol also inhibited the production of o 2 − radicals and h 2 o 2 even at low concentrations relevant for the respiratory air and in the therapeutic range . the essential cause of these antioxidative actions of 1 , 8 - cineol was surprisingly found to be 1 , 8 - cineol as active inducer of no production which , via this additional mechanism , removes o 2 − from the organism as substrate for the formation of no production . it has thus been found that monoterpenes such as 1 , 8 - cineol actively induce no production by mediating antioxidative effects . ( see table 2 ). table 2 shows the effect of 1 , 8 - cineol on the pma - stimulated superoxide production ( o 2 − production ) ( in rpmi 1640 ) of normal human monocytes in vitro . the dose - dependent effects of 1 , 8 - cineol ( 4 experiments , n = 9 - 14 ) on the o 2 − production were measured by determining int - formazan in culture supernatants ( rpmi 1640 ) of human monocytes ( 10 5 / ml ) after 20 hours . the o 2 − production was not stimulated by pma ( 500 mmol / l ). for statistical analysis , the non - parametric mann & amp ; whitney test was used ( p & lt ; 0 . 05 ). here , for the first time , it was possible to demonstrate modulating effects of 1 , 8 - cineol for controlling oxidative , cell - damaging and proinflammatory effects by inhibition of o 2 − radicals and a contrary stimulation of anti - inflammatory and vasodilatory no in the therapeutic range of 1 , 8 - cineol ( see fig3 ). fig3 shows the concentration - dependent modulating effects of 1 , 8 - cineol on o 2 − and no production in stimulated human monocytes in vitro : following stimulation ( 20 hours ) of normal human monocytes ( 10 5 / ml ), the production of no is induced and that of o 2 − is suppressed in the control ( i . e . without 1 , 8 - cineol ). in contrast , low concentrations of 1 , 8 - cineol slightly induce o 2 − production and , at subtherapeutic concentrations ( 0 . 15 μg / ml = 10 − 6 mol / l ), inhibit the production of no . in the therapeutic range of 1 , 8 - cineol , the o 2 − production is inhibited strongly in the presence of stimulating effects on the production of no (* p & lt ; 0 . 04 , ** p & lt ; 0 . 01 ). these results are of integral importance for the prophylaxis and therapy , in particular , of pulmonary disorders associated with cigarette smoking , including pulmonary emphysema and the regulation of the tone of pulmonary vessels , and also of damage to greater and lesser circulation . thus , an increased production of o 2 − radicals is mediated by cigarette smoke , infections , nanoparticles , ozone , allergens and other environmental effects , which production can be inhibited permanently by a long - term therapy with 1 , 8 - cineol and moreover can be utilized advantageously as a substrate for the production of no . no is known to be an anti - inflammatory mediator , vasodilator , inhibitor of inflammatory mediators , histamine , granulocyte adhesion and platelet aggregation and also as an activator of ciliary function and mucosal clearance and protects comprehensively against respiratory infections and exacerbations of asthma and copd in all disease stages . in this respect , 1 , 8 - cineol is suitable as a continuous therapeutic which , in chronic bronchitis , copd , emphysema and rhinosinusitis , by modulation , normalizes and adequately adapts to the respective requirements a suppressed no production by favourable degradation of o 2 − radicals with induction of no . this leads in particular to novel indications for the use of monoterpenes , in particular 1 , 8 - cineol , preferably in a relatively high , systemically effective daily dose , to regulate organ perfusion and to protect the upper and lower respiratory tracts including the lung against noxious substances acting as pathogens , in particular cigarette smoke and other emissions or fine dusts , respiratory infections and allergic and non - allergic respiratory inflammations in cases of hyperactivity , asthma and rhinitis . these hitherto unknown properties associated with the action of monoterpenes , in particular 1 , 8 - cineol , may contribute in establishing in the future , for the first time , the additional therapy with 1 , 8 - cineol in the literature and the therapy guidelines . 10 patients 56 to 72 years of age with persistent bronchial asthma ( gina ii ) treated with a combination therapy of inhalative glucocorticoid ( beclometasone , 2 × 200 μg / die by inhalation ) and inhalative long - acting beta - 2 - sympathomimetics ( laba , salmeterol ) and also oral theophyllin were given 1 , 8 - cineol ( soledum ® capsules ) 4 × 200 mg / die orally for one week . even after a one - week therapy at the dose mentioned above , in 8 of the 10 subjects a slight to moderate improvement of lung function was achieved . after continuing therapy for a further twelve weeks , the persistent bronchial asthma had stabilized to such an extent that in 7 of the 10 patients the inhalative glucocorticoid required could be reduced by up to 60 % and in 2 of the 10 patients the inhalative glucocorticoids could be discontinued altogether at times . the therapy was tolerated well , without any side - effects . in 5 of the patients treated , the betamimetics required , too , could be reduced by up to 40 %. a further 12 patients 59 to 78 years of age with persistent bronchial asthma ( gina iii ) treated with a combination therapy of inhalative glucocorticoid ( beclometasone , 2 × 400 μg / die by inhalation ) and inhalative long - acting beta - 2 - sympathomimetics ( laba , salmeterol ) and also oral theophyllin were given 1 , 8 - cineol ( soledum ® capsules ) 4 × 200 mg / die orally for one week . even after a one - week therapy at the dose mentioned above , in 9 of the 12 subjects a slight to moderate improvement of lung function was achieved . after continuing therapy for a further twelve weeks , the persistent bronchial asthma had stabilized to such an extent that in 9 of the 12 patients the inhalative glucocorticoid required could be reduced by up to 30 %. the therapy was tolerated well , without any side - effects . in 4 of the patients treated , the betamimetics required , too , could be reduced by up to 25 %. the results of the experiments show that monoterpenes significantly increase the efficacy of inhalative respiratory therapeutics , and that it is therefore possible to significantly reduce the amounts thereof which must be administered . in a placebo - controlled double - blind study , the effect of an additional therapy with 1 , 8 - cineol in the form of capsules which dissolve in the small intestine ( soledum ® capsules , 3 × 200 mg / die , oral ) on exacerbation rate and lung function was examined in 3 winter months of two successive years using 242 smokers with copd ( gold ii to iii ). both patient groups were identical with respect to age , sex , body mass index , smoker status , lung function and a guideline - conform medication of ics , laba , saba , anticholinergics and theophyllin . in the verum group , the additional therapy with 1 , 8 - cineol led to a significant reduction in the exacerbation rate of − 38 . 5 % compared to the placebo group . additionally , the lung function ( fev1 ) in the verum group (+ 5 . 1 %) had improved significantly compared to the placebo group (− 1 %). clinical parameters such as the st . george &# 39 ; s respiratory questionnaire ( sgrq ), too , had improved significantly more in the verum group (− 10 . 4 units ) compared to the placebo group (− 5 units ). thus , the results show , for the first time , that an additional therapy with 1 , 8 - cineol in the form of capsules which dissolve in the small intestine reduces the decrease , reported in the literature , in the frequency of exacerbations by the known combined therapeutic approaches involving budesonide and formoterol (− 24 %, 13 ) and fluticasone and salmeterol (− 25 %, 14 ) by a further 25 %. the findings reported above confirm a significant reduction of the inhalative ics dose of up to 60 % during a long - term therapy with oral 1 , 8 - cineol ( soledum ® capsules ). the essential clinical significance is the intensification of the anti - inflammatory action of minimal concentrations of customary ics ( for example metered aerosoles and powder preparations ) which decrease in the periphery of the lung . the use of 1 , 8 - cineol and ics is advantageous in particular in the therapy of a peripheral respiratory inflammation in copd as a novel therapeutic concept and for modulating the steroid - refractory progression of the pulmonary disorder , to prevent the development of irreversible respiratory insufficiency . of particular clinical value is , for example , the therapeutic use of 1 , 8 - cineol for the prophylaxis and therapy of early forms of copd ( i . e . gold 0 or gold i ), for which there is currently no anti - inflammatory therapy recommended by all lung associations world - wide . moreover , by a combined therapy of 1 , 8 - cineol and ics , the steroid - refractory respiratory inflammation caused by cigarette smoke and also other harmful proinflammatory and oxidative environmental substances such as , in particular , ozone ( o 3 ), and the development of copd is inhibited prophylactically and / or therapeutically . more detailed in vitro studies of the anti - inflammatory action of 1 , 8 - cineol , in particular in acute colds and / or chronic - obstructive respiratory disorders in vitro studies to determine the effects of an additional therapy with 1 , 8 - cineol and inhaled steroids ( ics ) on the production of superoxides ( o 2 − ) in normal human monocytes according to the current state of research , the applicant was able to demonstrate antioxidative actions of the active compound 1 , 8 - cineol , in addition to anti - inflammatory actions . the antioxidative action is based primarily on an inhibition of superoxides and an additional action by inhibition of the superoxide dismutase activity ( sod activity ), accompanied by a resulting inhibition of hydroperoxides ( h 2 o 2 ) which act in a proinflammatory manner on the transcription , with formation of cytokines and other inflammation mediators . systemic 1 , 8 - cineol , for example in the form of soledum ® capsules , can be employed — as discussed above — for example as additional therapy firstly for severe copd ( for example gold iii / iv ) and / or as monotherapy for mild forms ( for example gold i / ii ), i . e . also for chronic and acute bronchitis . it appears to be particularly worthy of mention that , for chronic bronchitis , the copd guideline ( gold ) does not suggest any anti - inflammatory or antioxidative therapy apart from avoidance of noxious substances . this constitutes a gap in the current guidelines which was closed in the context of the present application . in the more detailed studies of the applicant on 1 , 8 - cineol , it was possible to verify in principle the hypothesis that an additional therapy with systemic 1 , 8 - cineol in correlation with earlier and ongoing clinical studies with soledum ® capsules can mediate a potentiating superior antioxidative and / or anti - inflammatory action by enhancing the mediator inhibition in normal human monocytes . since an antioxidative effect of the standard therapy of severe copd consisting of , for example , laba plus ics has hitherto not been known , these newly recognized effects of 1 , 8 - cineol on the inhibition of superoxides compared to ics and laba ( 1 , 8 - cineol vs . ics and 1 , 8 - cineol plus ics ) have been examined for the first time in the context of the present invention . firstly , it was an object to examine the antioxidative effects of an additional therapy with 1 , 8 - cineol for inflammatory respiratory disorders ( for example copd or asthma ). since the action of 1 , 8 - cineol as comedication , in particular in combination with inhalative steroids and other guideline recommendations , has hitherto not been known , there is a need to develop novel principles to justify the novel therapeutic approach of using 1 , 8 - cineol for respiratory disorders . based on this knowledge it is an object to justify the present results of the clinical studies and to establish the strategy of the additional therapy by a new understanding . this is also the base for the examination of novel clinical issues concerning the use of 1 , 8 - cineol . the additional effect of 1 , 8 - cineol ( 4 × 10 − 6 mol / l and 6 × 10 − 6 mol / l ) is to be tested by co - incubation with therapeutically relevant concentrations ( 10 − 11 mol / l , 10 − 10 mol / l , 10 − 9 mol / l ) and higher concentrations ( 10 − 8 mol / 1 , 10 − 7 mol / l , 10 − 6 mol / l ) of beclometasone (“ becl .”). moreover , the effects of beclometasone on its own at the concentrations mentioned is to be determined in comparison to 1 , 8 - cineol . it is intended to test these effects on a combination of 1 , 8 - cineol and beclometasone (“ becl .”) as standard - ics on the fcs ( fetal calf serum )- stimulated production of o 2 − on normal human monocytes . the aim of the studies is to test additional effects of suboptimal ( 4 × 10 − 6 mol / l ) and optimal ( 4 × 10 − 6 mol / l ) concentrations of 1 , 8 - cineol on different concentrations of beclometasone . in vitro method for determining the additional effects of a co - incubation of 1 , 8 - cineol and beclometasone as already described , monocytes were isolated from 50 ml of venous blood which was repeatedly donated voluntarily for the experiments by healthy non - smoking subjects ( n = 4 ). the active compounds beclometasone and 1 , 8 - cineol were diluted with ethanol up to a maximum concentration of 0 . 01 %. the substances were incubated individually ( beclometasone 10 − 12 to 10 − 6 mol / l ) and in combination ( 10 − 11 to 10 − 9 mol / l beclometasone with 6 × 10 − 6 mol / l = 0 . 9 μg / ml 1 , 8 - cineol ) and also in an additional series at a 1 , 8 - cineol concentration which is not antioxidatively active ( 4 × 10 − 6 mol / l ). to this end , the active compounds were incubated together with freshly isolated monocytes ( 10 5 / ml ) and the fcs stimulus ( 10 %, from sigma ) for 20 hours in a cell culture medium ( rpmi - 1640 , from sigma ). the culture supernatants were then obtained after treatment of the cell membranes with triton - x 100 and immediately examined for production of o 2 − radicals . analytic method for the determination of superoxides ( o 2 − ) in culture supernatants of human monocytes the determination of the cytosolic superoxide production is based on the reduction of the dye p - iodonitrotetrazolium violet ( intv ), which reacts specifically with superoxide ions , to iodonitrotetrazolium formazan ( formazan ). intv is taken up by the cells into the cytosol . intracellularly , the nitrogen cycle of the intv is reduced by free superoxide radicals , giving rise to a water - soluble intermediate and the water - insoluble formazan , which have their absorption maxima at 505 and 490 nm , respectively . in contrast , intv does not absorb light of these wavelengths . at the end of an experiment , the cell lysate is ( after treatment with hydrochloric acid ) measured at 492 nm in a photometer . here , the absorption of light is proportional to the amount of intracellularly accumulated int - formazan which can then be determined using a formazan calibration curve . the int - formazan accumulation for its part is determined as a measure for the intracellular production of superoxide . crossreactions with 1 , 8 - cineol to make sure that true inhibitory effects of 1 , 8 - cineol on the int - formazan accumulation were present , possible crossreactions of 1 , 8 - cineol with the components of the measurement system were excluded . to this end , beclometasone 10 − 6 mol / l , 1 , 8 - cineol 10 − 5 mol / l , intv 0 . 5 mg / ml and also beclometasone 10 − 6 mol / l + 1 , 8 - cineol 10 − 5 mol / l + intv 0 . 5 mg / ml were incubated without cells and the int - formazan production was measured . neither 1 , 8 - cineol nor beclometasone on their own or in combination with intv had any detectable effect on the determination of the int - formazan production . crossreactions of 1 , 8 - cineol and beclometasone with the measurement method could therefore be excluded . studies on the dose - dependent production of o 2 − radicals in the various issues were carried out in key experiments with beclometasone ( expt . 3 , n = 10 to 11 ), 1 , 8 - cineol ( expt . 5 , n = 12 ), beclometasone + 1 , 8 - cineol 4 × 10 − 6 mol / l ( expt . 4 , n = 14 to 15 ) and beclometasone + 1 , 8 - cineol 6 × 10 − 6 mol / l ( expt . 3 , n = 11 to 12 ). effects of 1 , 8 - cineol and beclometasone are expressed as “% of the fcs control ” and were examined statistically using the non - parametric mann & amp ; whitney test . p values & lt ; 0 . 05 are considered to be statistically significant . comparison of the effects of beclometasone and 1 , 8 - cineol on the fetal calf serum ( fcs )- stimulated production of superoxides ( o 2 − ) in normal human monocytes monocytes ( 10 5 / ml ) were incubated with different concentrations of beclometasone ( 10 − 12 to 10 − 6 mol / l , n = 10 - 11 ) for 20 hours together with the fcs stimulus ( 10 %). a borderline significant inhibition (− 10 . 5 ± 5 %, p = 0 . 0910 ) of the o 2 − production was demonstrated only for beclometasone 10 − 9 mol / l ( see table 3 ). high concentrations 10 − 8 mol / l ) of beclometasone stimulated the monocyte o 2 − production , with a significant increase ( 15 . 2 ± 2 . 5 %, p = 0 . 0092 ) at 10 − 6 mol / l ( see fig4 ). thus , an inhibition of the o 2 − production could not be demonstrated for beclometasone . in contrast to the action of beclometasone , a strong inhibition of the o 2 − production (− 42 . 6 ± 8 %, p = 0 . 0007 ) was demonstrated for 1 , 8 - cineol even at a therapeutically relevant concentration ( 0 . 9 mg / ml = 6 × 10 − 6 mol / l ). in contrast to beclometasone , which at therapeutic concentrations does not inhibit the o 2 − production and at higher concentrations stimulates the o 2 − production , 1 , 8 - cineol inhibited the o 2 − production in the therapeutic range . the inhibition profile of these different actions of the substances is shown in a comparative manner in fig5 . effect of a suboptimal concentration ( 0 . 6 μg / ml ) of 1 , 8 - cineol + beclometasone on the fcs - stimulated production of superoxides ( o 2 − ) in normal monocytes owing to the different activity profiles found for beclometasone and 1 , 8 - cineol , additive or synergistic actions of the two substances were investigated . co - incubations even of a concentration of 1 , 8 - cineol which is itself not yet oxidatively active with beclometasone ( n = 14 - 15 ) were initiated under the experimental conditions described to examine a possible synergistic action of the two substances . the chosen concentration of 1 , 8 - cineol 4 × 10 − 6 mol / l on its own showed no effect ( 9 ± 6 %, p = 0 . 2717 ), and neither did the concentrations of beclometasone examined 10 − 11 to 10 − 9 mol / l ( see table 5 ). in contrast to the not significantly inhibiting properties of the individual substances , a likewise not significant borderline increase of the o 2 − production was demonstrated for 1 , 8 - cineol + beclometasone 10 − 10 mol / l ( 2 ± 7 %, p = 0 . 7557 ) and for 1 , 8 - cineol + beclometasone 10 − 9 mol / l ( 4 ± 8 %, p = 0 . 8519 ). a therapeutically relevant borderline concentration of 1 , 8 - cineol 6 × 10 − 6 mol / l ( 0 . 9 mg / ml ) was determined as lowest antioxidatively active concentration for 1 , 8 - cineol , and this concentration inhibited the o 2 − production significantly (− 50 . 2 ± 5 %, & lt ; 0 . 0001 ). in this experimental series , too , beclometasone 10 − 11 to 10 − 9 mol / l on its own had no detectable effect on the o 2 − production ( see table 6 ). co - incubation of 1 , 8 - cineol + beclometasone 10 − 11 mol / l inhibited the o 2 − production (− 49 . 9 ± 5 %, p & lt ; 0 . 0001 ), and this effect is comparable ( p = 0 . 9215 ) to the effect of 1 , 8 - cineol on its own . with increasing concentration of beclometasone ( 10 − 9 mol / l ) in the presence of 1 , 8 - cineol , the antioxidative action tends to decrease , reaching − 38 . 1 ± 3 % ( p & lt ; 0 . 0001 ) ( see fig6 ). statistical analyses show that the inhibition of the o 2 − production by 1 , 8 - cineol + beclometasone 10 − 10 mol / l (− 40 . 9 ± 3 %) is significantly weaker ( p & lt ; 0 . 0001 ) compared to 1 , 8 - cineol on its own . the same also applies to 1 , 8 - cineol + beclometasone 10 − 9 mol / l . also , compared to 1 , 8 - cineol + beclometasone 10 − 11 mol / l , the slightly decreasing inhibition of the o 2 − production in the presence of higher doses of beclometasone for 1 , 8 - cineol + beclometasone 10 − 10 mol / l ( p = 0 . 0165 ) and 1 , 8 - cineol + beclometasone 10 − 9 mol / l ( p = 0 . 0053 ) is significant . these data show that the activity of 1 , 8 - cineol is weakened by the properties of beclometasone ( 10 − 10 and 10 − 9 mol / l ) and that in the combination with beclometasone the leading role of the antioxidative activity is mediated by 1 , 8 - cineol — without 1 , 8 - cineol it cannot be detected in this combination ( see fig7 ). the present results of the study show that a frequently employed inhalative steroid such as beclometasone does not inhibit and at a no longer therapeutically relevant high concentration ( 10 − 6 mol / l ) even significantly increases the stimulated production of o 2 − radicals in monocytes . in contrast , the production of o 2 − radicals is inhibited by therapeutically relevant concentrations of 1 , 8 - cineol by about 50 %. accordingly , for the first time , the present study now shows that the strong inhibition of the production of o 2 − radicals by therapeutic concentrations of 1 , 8 - cineol in combination with beclometasone can be demonstrated and provides an advantage which cannot be mediated in an isolated manner by the inhalative steroid alone . this is not a purely additive effect but the mediation of the effect of 1 , 8 - cineol on the combination of 1 , 8 - cineol and beclometasone , without it being possible to detect an independent antioxidative effect of beclometasone . the lack of any indication of an inhibition of the formation of o 2 − radicals by beclometasone is presumably indicative of the stimulation of o 2 − radicals found for higher , not therapeutically relevant concentrations of beclometasone . the results show that there is an interaction between beclometasone and 1 , 8 - cineol which , at high doses of beclometasone , decreases the potent action of 1 , 8 - cineol in a negative - synergistic manner . this is evidenced by the fact that 1 , 8 - cineol on its own has a significantly stronger antioxidative action than in combination with beclometasone , and that even the activity of 1 , 8 - cineol + beclometasone decreases significantly at increasing concentrations of beclometasone compared to a combination with a smaller beclometasone concentration . besides , further investigations show that fluticasone , too , induces the production of o 2 − radicals , and that this takes place via an inhibition of superoxide dismutase , which metabolizes o 2 − to h 2 o 2 . these effects also increase with increasing steroid receptor binding capability , and the present studies therefore suggest that inhaled steroids are at least not capable of developing any antioxidative action via the inhibition of o 2 − radicals and very likely do not at all act as antioxidants . as far as this is concerned , the investigations show that 1 , 8 - cineol , at least with respect to its surprising superior antioxidative action compared with the steroids used to date , mediates an advantageous , hitherto underestimated activity profile in the respiratory tract . this alone is the reason for the additional therapy with 1 , 8 - cineol of inflammatory respiratory disorders and makes a long - term therapy particularly recommendable . since the development of copd treated with ics is delayed owing to a reduction of exacerbations , but still progresses when treated with a combined therapy , the lack of antioxidative activity in the medication currently available may play an essential role here . the progression of copd is accelerated in particular by smoking cigarettes , which leads to a high deposition of inhaled o 2 − radicals in the respiratory tract , which radicals can obviously not be inactivated by ics or a combined therapy with laba plus ics , or the therapy is not sufficiently protectively active with respect to epithelial cells of the respiratory tract and macrophages , and it is therefore conceivable that the pathogenic stimulus persists and contributes to the progression of the respiratory disorder . another novel aspect of the present invention is the systemic inflammation , hitherto underestimated , in copd , which inflammation is induced by smoking cigarettes , but also by the severity of the disorder . as far as this is concerned , the inhalative local therapy is presumably not sufficient to actually control the course of copd . likewise , the present data may also explain the lack of any effects of a systemic therapy of copd with prednisolone which , in the presence of a nicotine - induced steroid resistance , promotes inflammation prooxidatively . accordingly , in the future a new importance may be attributed to the substance 1 , 8 - cineol . moreover , owing to a confirmed local and systemic inflammatory reaction , copd cannot be treated satisfactorily by an inhalative combined therapy alone , so that further foundations for new core statements with respect to the active compound 1 , 8 - cineol are increasingly being developed by the external support of world - wide research efforts , which will have to be implemented in an appropriate manner . in summary , the present data open up a very current and hitherto underestimated perspective which helps in the understanding of the novel range of indications for 1 , 8 - cineol on a local level in spite of systemic administration . at the same time , this also provides new options as the compatibility has to be looked at as a consequence of interactions with different comedications . the adopted procedure will help in the correct assessment of the substance 1 , 8 - cineol with respect to its action and the clinical use for respiratory disorders that can be derived therefrom .
the invention relates to the combined use of at least one monoterpene which can be applied systemically , in particular perorally , and at least one respiratory tract therapeutic agent which can be applied topically , in particular through inhalation , for the prophylactic and / or therapeutic treatment , in particular combination therapy and / or co - medication , of respiratory tract diseases , in particular bronchopulmonary diseases . through the combined use of the systemic monoterpene with the topical , in particular inhaled respiratory tract therapeutic agent , the effect or efficiency of the topical or inhaled respiratory disease therapeutic agent can be increased significantly , in particular in a synergistic manner , on the one hand , and the required dosage thereof can be reduced significantly on the other hand , combined with the resulting advantages .